phentolamine mesylate
Trade name: regitine
Approved
Jan 30, 1952
Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha-adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output. Phentolamine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine is also indicated for the diagnosis of pheochromocytoma by the Phentolamine blocking test. Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur. — NCATS
Clinical trial activity
44 trials · 55 clinical orgs · 6 marketing orgs
Earliest trial started Aug 1, 2001 (NCT00080808)
Timeline
1950s
1990s
- Mar 11, 1998
West-Ward Pharmaceutical — Marketing Organization
- Mar 11, 1998
Hikma — Marketing Organization
2000s
2010s
- Jul 14, 2017
Precision Dose — Marketing Organization
Indications
Studied for
- Acute Coronary Syndrome · Phase 2/Phase 3
- Acute Kidney Injury · Phase 2/Phase 3
- Adrenergic Antagonists · Phase 2/Phase 3
- Anesthesia · Phase 4
- Anesthesia, Dental · Phase 4
- Anesthesia, Local · Phase 4
- Breast Neoplasms · Phase 1
- Coronary Artery Disease · Phase 2/Phase 3
- Dilatation · Phase 3
- Erectile Dysfunction · Phase 2/Phase 3
- Glaucoma, Open-Angle · Phase 2
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 1
- HIV Infections · Phase 2
- Hypertension · Phase 3
- Hypertension, Pulmonary · Phase 1
- Insulin Resistance · Phase 1
- Ischemic Stroke · Phase 3
- Melanoma · Phase 1
- Mesopic Vision · Phase 3
- Mydriasis · Phase 3
- Night Blindness · Phase 3
- Obesity · Phase 1
- Ocular Hypertension · Phase 2
- Pre-Eclampsia · Phase 4
- Presbyopia · Phase 3
- Prostatic Neoplasms · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 1
- Soft Tissue Injuries · Phase 3
- Vasoconstriction · Early Phase 1
- Vasodilation · Early Phase 1
- Vision Disorders · Phase 3
Mechanism of action
- Adrenergic receptor alphaANTAGONIST
Adrenergic receptor alpha antagonist
Approval history
- approvedPriority reviewJan 30, 1952
Chemistry & pharmacology
SMILES
Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1- Mol. weight
- 281.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL597 ↗
- WikipediaPhentolamine ↗
- NCATSZ468598HBV ↗
- ChEMBLCHEMBL1204146 ↗
- ChEMBLCHEMBL1200873 ↗
Also known as
- 2-(n-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
- 2-(n-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
- fentolamina
- fentolamina
- fentolamine
- oraverse
- oraverse
- oraverse
- phentholamine
- phentolamin
- phentolamin
- phentolamine
- phentolamine
- phentolamine
- phentolamine
- phentolamine
- phentolamine
- phentolamine
- phentolamine
- phentolamine
- phentolamine
- phentolamine hcl
- phentolamine hydrochloride
- phentolamine mesilate
- phentolamine mesilate
- phentolamine mesilate
- phentolamine mesylate
- phentolamine mesylate
- phentolamine mesylate
- phentolamine mesylate
- phentolamine mesylate
- phentolamine mesylate
- phentolamine methanesulfonate
- phentolamine methanesulfonate
- phentolaminum
- phentolaminum
- regitina
- regitina
- regitine
- regitine
- regitine
- rogitine
- rogitine
- trimix
- trimix
- vesomax
- vesomax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07140783 | Phase 3 | Sep 2, 2025 | Ocuphire Pharma, Inc. |
| NCT07012512 | N/A | Jun 1, 2025 | Mansoura University |
| NCT06620991 | N/A | Oct 10, 2024 | Ain Shams University |
| NCT06422494 | N/A | Sep 30, 2024 | Radboud University |
| NCT06542497 | Phase 3 | Aug 15, 2024 | Ocuphire Pharma, Inc. |
| NCT06385600 | N/A | May 20, 2024 | Assiut University |
| NCT06349759 | Phase 3 | Apr 1, 2024 | Ocuphire Pharma, Inc., Viatris |
| NCT06286059 | Phase 2/Phase 3 (Phase 3) | Mar 7, 2024 | Helwan University |
| NCT05687669 | Phase 4 | Jan 12, 2023 | Assiut University |
| NCT05646719 | Phase 3 | Dec 12, 2022 | Ocuphire Pharma, Inc. |
| NCT05448807 | Phase 3 | Oct 31, 2022 | Cairo University |
| NCT05525416 | N/A | Jul 28, 2022 | University of Alberta |
| NCT05223478 | Phase 3 | Dec 17, 2021 | Ocuphire Pharma, Inc. |
| NCT05473858 | Phase 3 | Dec 10, 2021 | Al Azhar University |
| NCT05134974 | Phase 3 | Nov 18, 2021 | Ocuphire Pharma, Inc. |
| NCT04675151 | Phase 2 | Jan 31, 2021 | Ocuphire Pharma, Inc. |
| NCT04638660 | Phase 3 | Dec 30, 2020 | Ocuphire Pharma, Inc. |
| NCT04620213 | Phase 3 | Nov 18, 2020 | Ocuphire Pharma, Inc. |
| NCT04436731 | Early Phase 1 (Phase 1) | Jul 1, 2020 | University of Missouri |
| NCT04024891 | Phase 2 | Jul 31, 2019 | Ocuphire Pharma, Inc. |
Organizations
Research & Development (55)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ocuphire Pharma, Inc. | For profit | 12 | 12 | 2 | 2007 |
| Novalar Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2003 |
| Free University of Brussels | Academic/Hospital | 3 | 1 | 2 | 2009 |
| Assiut University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| Dalhousie University | Academic/Hospital | 2 | 2 | 2 | 2015 |
| eTheRNA | For profit | 2 | 0 | 2 | 2017 |
| National Health and Medical Research Council, Australia | Government | 2 | 0 | 2 | 2005 |
| Radboud University | Academic/Hospital | 2 | 2 | 1 | 2005 |
| Tufts University | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of Barcelona | Academic/Hospital | 2 | 1 | 2 | 2015 |
| University of New South Wales | Academic/Hospital | 2 | 2 | 2 | 2005 |
| University of Pennsylvania | Academic/Hospital | 2 | 1 | 2 | 2012 |
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Al Azhar University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Asphalion | For profit | 1 | 0 | 1 | 2017 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Benha University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | Government | 1 | 0 | 1 | 2012 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2009 |
Marketing (7)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Deproco | For profit | NDA2 | May 9, 2008 |
| Hikma | For profit | MKTG | Mar 11, 1998 |
| Novartis | For profit | NDA2 | Jan 30, 1952 |
| Novartis | For profit | NDA | Jan 30, 1952 |
| Precision Dose | For profit | MKTG | Jul 14, 2017 |
| Septodont | For profit | NDA2 | May 9, 2008 |
| West-Ward Pharmaceutical | For profit | MKTG | Mar 11, 1998 |